Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Sagimet (NASDAQ: SGMT) provided strategic and corporate updates on April 27, 2026, focusing on dermatology advancement and portfolio prioritization.
The company plans a U.S. Phase 3 trial of oral denifanstat for moderate to severe acne in the second half of 2026, subject to IND clearance, and reported positive topline safety results from a China Phase 3 open-label trial (n=240) of 50 mg once-daily denifanstat. Ongoing programs include a first-in-human Phase 1 trial of FASN inhibitor TVB-3567, a completed Phase 1 PK study for denifanstat+resmetirom, and a pause on further MASH development until non-dilutive funding is secured. New CMO appointment and an investor KOL webcast on April 30, 2026 were announced.
Sagimet Biosciences (Nasdaq: SGMT) appointed Andreas Grauer, MD as Chief Medical Officer effective April 20, 2026; prior CMO Eduardo Bruno Martins retired and will serve as an external scientific advisor.
Dr. Grauer has 20+ years of global clinical development experience. Sagimet approved an inducement stock option valued at $1,340,000 (Black Scholes value) granted April 20, 2026, with a ten-year term and four-year vesting; exercise price equals the closing Nasdaq price on April 20, 2026.
Sagimet (Nasdaq: SGMT) will present Phase 2b FASCINATE-2 data at the Fueling MASH Keystone Symposium April 12-15, 2026 in Vancouver.
In denifanstat-treated MASH patients, histological responders showed significant reductions in glycine- and taurine-conjugated bile acids at 26 weeks. Sagimet also granted an inducement award of 9,600 stock options on April 3, 2026 to a new hire; options vest over four years and carry a ten-year term.
Sagimet Biosciences (Nasdaq: SGMT) reported 2025 year-end results and clinical progress on March 11, 2026. Key items: $113.1M cash balance, completion of a Phase 1 PK trial of denifanstat plus resmetirom with no safety signals, an exclusive global license to TAPI resmetirom API, and NMPA acceptance of an NDA for denifanstat in acne.
Planned near-term milestones include a Phase 2 proof-of-concept trial in F4 MASH in 2H 2026 and anticipated Phase 2 acne studies for TVB-3567 in 2026.
Sagimet Biosciences (Nasdaq: SGMT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 2 (Boston), Leerink on March 9 (Miami) and Citizens Life Sciences on March 10 (Miami).
TD Cowen and Leerink fireside chats will be webcast and archived for 90 days on the company's investor site.
Sagimet Biosciences (Nasdaq: SGMT) announced management will participate in two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 at 10:00 AM ET and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 9:20 AM ET.
Both fireside chats will be webcast in the Investors & Media section at www.sagimet.com, with archived replays available for 90 days after each live event.
Sagimet (Nasdaq: SGMT) announced Ascletis reported positive 52-week safety results from an open-label Phase 3 trial of ASC40 (denifanstat) 50 mg once daily in moderate-to-severe acne.
The 240-subject open-label study showed denifanstat generally well tolerated through up to 52 weeks, with dry eye (5.5%) and dry skin (5.2%) as the only TEAEs ≥5%; no denifanstat-related Grade 3/4 AEs, no denifanstat-related SAEs, and efficacy endpoints improved versus 12-week data.
Ascletis (HKEX:1672) announced positive topline results from a Phase III open-label safety study of denifanstat (ASC40), a once-daily oral FASN inhibitor for moderate-to-severe acne. The 240-patient, 40-week trial reported a favorable safety and tolerability profile with mostly grade 1–2 TEAEs, no ASC40-related grade 3–4 AEs, no ASC40-related SAEs, and no deaths.
Ascletis also referenced a prior 480-patient randomized, double-blind Phase III trial that met all primary and key secondary endpoints in June 2025, and noted that a New Drug Application for ASC40 was recently accepted by the China National Medical Products Administration.
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.
Sagimet Biosciences (NASDAQ: SGMT) reported positive Phase 1 pharmacokinetic (PK) results for a once-daily combination of denifanstat and resmetirom on Dec 18, 2025. The open-label, 2-cohort PK study (NCT07216313) enrolled 40 healthy adults to evaluate multiple- and single-dose PK, drug-drug interactions, safety, and tolerability. The combination was generally well-tolerated with no serious adverse events, no treatment discontinuations, and no clinically significant lab abnormalities. Sagimet plans to use these data to pursue a Phase 2 proof-of-concept efficacy trial in MASH with F4 fibrosis, aiming to initiate the study in 2H 2026, subject to regulatory consultation, and noted a global license agreement for resmetirom API forms to support a fixed-dose combination development.